1910 Genetics Case Study

1910 Genetics ("1910"), is the only biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation. 1910 integrates AI with three proprietary data streams—computational data, wet lab proxy biological data, and wet lab ground truth biological data—to deliver innovative drug candidates and software technologies to prominent pharma and tech partners.

Challenge

Like many innovative startups in biotech, 1910 Genetics faced three key challenges as they began their journey: building a cutting-edge lab efficiently, forging meaningful pharmaceutical partnerships in a competitive landscape, and securing the funding essential for sustainable growth.

Setting up and managing a state-of-the-art laboratory requires careful planning—especially for a young company balancing resources. Equipment costs add up quickly, specialized knowledge is needed, and operational logistics can become complex while a team is finding its scientific footing.

Meanwhile, in Cambridge's dynamic biotech ecosystem, connecting with pharmaceutical giants requires more than just innovative science—it requires the right opportunities to showcase your platform's potential. For 1910, these partnerships were essential steppingstones to bring their AI-powered drug discovery vision to life.

Solution

The two years 1910 Genetics spent at LabCentral provided valuable hands-on experience in laboratory operations that prepared them well for establishing their own facility in Boston's Seaport District. LabCentral's supportive infrastructure offered a blueprint for how to build and operate a lab efficiently—knowledge that proved beneficial as they scaled.

But perhaps even more valuable was the proximity to industry leaders. At LabCentral, connections that might have taken longer to develop elsewhere happened naturally, creating pathways for collaboration that supported 1910's growth trajectory.

Results

Science

“We owe a lot of gratitude to the LabCentral Biology Operations Team for patiently teaching us the ins and outs of lab operations."

Jen Asher

Founder & CEO

1910 Genetics

Business

“LabCentral’s network opened doors to invaluable opportunities for us, including a research collaboration with a leading pharma company in immunology. Their leadership also provided investor references that played a key role in helping us secure funding.”

Jen Asher

Founder & CEO

1910 Genetics

People

“Our time at LabCentral facilitated positive collisions with Big Pharma companies. We were literally bumping into them in the halls! This proximity led to a research collaboration with a top 5 pharma company in the immunology space."

Jen Asher

Founder & CEO

1910 Genetics